Quantitative Determination of Naltrexone Hydrochloride in a Nasal Spray by High-performance Liquid Chromatography

Introduction. Naltrexone, an antagonist of µ-opioid receptors, is promising for the treatment of various autoimmune and oncological diseases when used in doses of 1.5–5 mg/day. To date, there are no medications that provide such dosages of naltrexone.Aim. Development and validation of a method for the quantitative determination of naltrexone hydrochloride in a nasal spray by high performance liquid chromatography (HPLC).Materials and methods. As an object of research, a naltrexone hydrochloride nasal spray was used. The quantitative determination of naltrexone in the test sample was developed using a Dionex UltiMate 3000 high-performance liquid chromatograph (Thermo Scientific, USA) equipped with a diode-matrix detector.Results and discussion. The possibility of using isocratic and gradient chromatographic modes for the quantitative determination of naltrexone hydrochloride in the nasal spray was studied. Based on these results, a new method of determination using the gradient mode is proposed, which allows minimizing the influence of the polymer component in the test sample on the analysis results.Conclusion. A new technique of high-performance liquid chromatography (HPLC) is proposed that allows identification and quantification of naltrexone hydrochloride in a nasal spray containing a high concentration of water-soluble heat-sensitive poloxamer as a thickener. The developed method was validated according to the parameters: correctness, precision, specificity, linearity.

• Publication year

  2020

• Venue

  Drug development & registration

• Publication date

  2020-05-30

• Fields of study

  Not labeled

• Identifiers
  DOI 10.33380/2305-2066-2020-9-2-98-104
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.

  2018cited by this paper
• Development and validation of a bioanalytical method for the simultaneous determination of heroin, its main metabolites, naloxone and naltrexone by LC-MS/MS in human plasma samples: Application to a clinical trial of oral administration of a heroin/naloxone formulation.

  2015cited by this paper
• Naltrexone: Not Just for Opioids Anymore

  2015cited by this paper
• Bernard Bihari, MD: low-dose naltrexone for normalizing immune system function.

  2013cited by this paper
• Electromembrane extraction of trace amounts of naltrexone and nalmefene from untreated biological fluids.

  2011cited by this paper
• Reverse Phase-HPLC method for the analysis of Naltrexone hydrochloride in bulk drug and its pharmaceutical formulations

  2010cited by this paper
• An automated, highly sensitive LC-MS/MS assay for the quantification of the opiate antagonist naltrexone and its major metabolite 6beta-naltrexol in dog and human plasma.

  2008cited by this paper
• Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 6beta-naltrexol in guinea pig plasma.

  2004cited by this paper

• Quantitative Determination of Benzalconium Chloride in the Naltrexone Hydrochloride Nasal Spray

  2020cites this paper